Provides structured US market access for EvoLiver FDA-designated liver cancer surveillance test across health systems, payors and clinical stakeholders

Cambridge, UK, and Boston MA, USA, 04 March 2026: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve chronic disease outcomes for at-risk patients, today announced it has been selected to join the Association of British HealthTech Industries (ABHI) US Accelerator. Building on the Company’s US presence, the programme will support the introduction of EvoLiver^™, its FDA-designated liver cancer surveillance test, to the US market.

The ABHI programme will provide Mursla Bio with structured access to more than 300 senior healthcare leaders across 35 leading hospitals, 20 health systems, and US insurers. It also offers direct operational guidance from Becton Dickinson, Dell Medical School at the University of Texas, and ABHI’s US advisor network. This access is expected to accelerate EvoLiver’s path into clinical workflows, helping convert launch readiness into early adoption across specialist hepatology centres.

Mursla Bio continues to advance US launch preparations for EvoLiver, including CLIA lab preparation, engagement with key opinion leaders and clinical societies, and payor dialogue. EvoLiver is a blood test designed to improve liver cancer detection in high risk patients by leveraging hepatocyte-specific EV biology, addressing key limitations of standard approaches.

Liver cancer remains one of the fastest-growing causes of cancer-related mortality in the US, with gaps in both surveillance performance and patient adherence contributing to late diagnosis. Mursla Bio is pursuing a hepatology-led, guideline-aligned commercial strategy, with broader expansion over time as additional clinical evidence supports wider coverage and adoption.

Pierre Arsène, Founder and CEO of Mursla Bio, said: “Bringing a new test into clinical use depends on reaching the right people across the healthcare system. This programme strengthens those connections while supporting EvoLiver’s early deployment and laying the commercial foundations for our EV diagnostics platform in the US.”

ENDS

About Mursla Bio

Mursla Bio is a biotech company on a mission to significantly improve chronic disease outcomes for at-risk patients through the power of Dynamic Biopsy. The Company’s proprietary biopsy platform non-invasively analyzes living biological processes within a specific organ or tissue to assess its health condition. This approach combines the accuracy and disease sub-typing capabilities of tissue biopsies with the ease of liquid biopsy sample collection.

Dynamic Biopsy is made possible by advanced extracellular vesicle (EV) science and an innovative approach called extracellular omics, supported by Mursla Bio’s pioneering technologies. These technologies include physical organ-specific EV isolation from biofluids for precise targeting, an AI-enabled multi-omics workflow spanning across proteins, miRNAs and mRNAs and a scalable clinical assay platform optimized for clinical validity and utility.

The Company’s AI Precision Medicine Platform underpins this technology, offering a full-stack infrastructure for biomarker discovery, assay development, and precision diagnostic productization across disease areas, grounded in real-world clinical datasets rather than static tissue atlases.

Mursla Bio is initially focused on transforming the surveillance of liver cancer in high-risk populations - the fastest growing cause of cancer related deaths. Mursla Bio is developing its first Dynamic Biopsy-based blood test, EvoLiver™ alongside synergistic precision medicine applications.

Mursla Bio is based in Cambridge, UK and Boston, MA.

For more information please visit: www.mursla.com